Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun 16;2(6):574-82.

Comparison of Bcl-2, CD38 and ZAP-70 Expression in Chronic Lymphocytic Leukemia

Rachel L Sargent  1 , Fiona E Craig, Steven H Swerdlow
Affiliations

Comparison of Bcl-2, CD38 and ZAP-70 Expression in Chronic Lymphocytic Leukemia

Rachel L Sargent et al. Int J Clin Exp Pathol. .

Abstract

Chronic lymphocytic leukemia (CLL) was previously considered a uniform disease characterized by autonomous over-expression of bcl-2. Recently the pathogenic role of bcl-2 has been questioned and attention has turned to prognostic subtypes of CLL differing in CD38 and ZAP-70 expression. However, the relationship between bcl-2 and CD38 or ZAP-70 expression remains uncertain and was investigated using flow cytometric immunophenotyping of 50 CLL specimens. CLL cells were consistently bcl-2 positive but varied in expression level: mean fluorescence intensity (MFI) 45-152. Although there was no significant difference in bcl-2 expression between CD38 or ZAP-70 positive and negative specimens, an inverse correlation was identified between percentage of CD38 positive B-cells and bcl-2 MFI when all (p<0.03, r(2)=0.10) and peripheral blood (p<0.004, r(2)=0.27) samples were analyzed. While bcl-2 levels do not appear to be a major discriminator between indolent and more aggressive subtypes of CLL, CD38 and bcl-2 expression appear to be interrelated.

Keywords: CD38; ZAP-70; bcl-2; chronic lymphocytic leukemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison between bcl-2 expression in B-cells and non-B lymphoid cells. B-cells demonstrate significantly higher bcl-2 MFI than non B-lymphoid cells (p<0.0001).
Figure 2
Figure 2
Comparison between bcl-2 MFI and the percentage of CD38 positive B-cells in peripheral blood samples, demonstrating an inverse correlation (p<0.004, r2=0.27).
Figure 3
Figure 3
Flow cytometric dot-plots illustrating bcl-2 expression of 19 positive B-cells and CD19 negative non B-lymphoid cells. (A) Sample with high bcl-2 expression in CLL cells (MFI-R > 1.7). (B) Sample with low bcl-2 expression in CLL cells (MFI-R < 1.7).
See this image and copyright information in PMC

References

    1. Packham G, Stevenson FK. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology. 2005;114:441–449. - PMC - PubMed
    1. Goolsby C, Paniagua M, Tallman M, Gartenhaus RB. Bcl-2 regulatory pathway is functional in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2005;63:36–46. - PubMed
    1. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol. 1999;17:399–408. - PubMed
    1. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood. 1998;91:3379–3389. - PubMed
    1. Schena M, Larsson LG, Gottardi D, Gaidano G, Carlsson M, Nilsson K, Caligaris-Cappio F. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood. 1992;79:2981–2989. - PubMed

LinkOut - more resources